Private Equity Anesthesia: Top Firms in 2026

Key Facts

• The US anesthesiology services market is valued at $26.2 billion, supporting approximately 100 million surgical procedures annually.
• Anesthesiology accounts for roughly 20% of all PE physician practice buyouts, the highest proportion of any single medical specialty.
• The 8 largest anesthesia physician management companies employ approximately 22% of all US anesthesia practitioners.
• PE-backed anesthesia management companies increased allowed reimbursement amounts by 26% on average, compared to 12.9% for non-PE firms, per a 2022 JAMA Internal Medicine study.
• Private equity firms now own approximately 488 US hospitals, representing 8.5% of all private hospitals; Texas leads with 108 PE-owned facilities.
• Welsh Carson Anderson & Stowe, the creator of U.S. Anesthesia Partners, agreed to a final FTC consent order in May 2025 limiting future anesthesia investments.
• At least 19 states introduced legislation in 2025 to regulate private equity in healthcare, with California recently passing restrictions on PE healthcare transactions.

Anesthesiology Private Equity Overview

Anesthesiology became one of the most aggressively consolidated medical specialties in US healthcare over the past decade. Private equity firms identified a fragmented market of independent practices servicing hospitals under high-volume, high-margin exclusive contracts. They then deployed roll-up strategies to consolidate those contracts under centrally managed physician management companies (PMCs). The result is a specialty where private equity anesthesia investment has reshaped both the employment landscape for clinicians and the cost structure for patients and insurers.

PE firms have acquired approximately one-third of all US anesthesiologists through physician practice buyouts. The 8 largest anesthesia PMCs now employ nearly 22% of the country's anesthesia workforce. This concentration gives PE-backed PMCs significant leverage in payer negotiations, a dynamic that research consistently links to higher reimbursement rates and patient costs.

Texas serves as the clearest case study of this model's reach and consequences. U.S. Anesthesia Partners (USAP), which Welsh Carson Anderson & Stowe created in 2012, grew to handle nearly half of all hospital-only anesthesia cases in the state. It captures approximately 60% of all hospital anesthesia revenue paid by Texas commercial insurers. North American Partners in Anesthesia (NAPA) operates across 500 facilities in 21 states, and PE-backed hospital systems with embedded anesthesia departments span the country.

PE investors collectively own 488 US hospitals as of 2025, representing 8.5% of all private hospitals. New Mexico has the highest concentration at 36.2% of all private hospitals in the state. The South is disproportionately represented in PMC-contracted facilities, accounting for 43% of such facilities versus 32% for matched controls.

Anesthesiology PE Firms: Comparison

These buyout firms and investment groups represent the primary investors shaping the anesthesia market, from physician management roll-ups to large hospital system acquisitions.

Welsh Carson and the American Securities/Leonard Green partnership are the purest anesthesia plays on this list. KKR, Blackstone, and Apollo participate through larger physician staffing and hospital system investments where anesthesia departments are embedded rather than standalone targets.

Top Picks by Investment Strategy

Most Active Anesthesia Roll-Up: Welsh Carson Anderson & Stowe created USAP in 2012, directed the acquisition of 15+ Texas anesthesia practices, and achieved approximately 36% control of the Texas anesthesia market before FTC enforcement action.

Largest National Anesthesia Staffing Platform: American Securities and Leonard Green & Partners jointly own NAPA, which employs 6,000 clinicians at 500 facilities across 21 states, making it the nation's largest anesthesia staffing organization by headcount.

Largest Hospital System Owner: Apollo Global Management controls Lifepoint Health and ScionHealth with 235 combined hospital facilities, embedding anesthesia departments across the country's most extensive PE-owned hospital network.

Biggest Single Physician Staffing Deal: KKR acquired Envision Healthcare for $9.9 billion in 2018, the largest PE investment in a physician staffing company, covering anesthesiology departments at more than 1,800 clinical locations in 45 states.

Growth Equity Leader: TPG Growth purchased a controlling stake in NorthStar Anesthesia in 2013 and retained a minority position after selling the majority to Cranemere Group in 2018, demonstrating a staged growth equity approach rather than a pure roll-up.

Longest-Tenured Surgical Footprint: Bain Capital is the largest shareholder of Surgery Partners with a 40% stake across 161 surgical locations in 31 states. The firm submitted a proposal in January 2025 to take the company fully private.

Most Consequential Early Exit: Hellman & Friedman backed Sheridan Healthcare before its $2.35 billion acquisition by AmSurg in 2014, establishing the first major-scale exit template in the specialty.

Detailed Profiles: Top Anesthesia Investors

Welsh Carson Anderson & Stowe (WCAS)

The defining firm in the anesthesia PE market, Welsh Carson manages approximately $31 billion in assets under management. The fund built the US anesthesia market's most scrutinized roll-up by creating U.S. Anesthesia Partners. Welsh Carson founded USAP in 2012 and directed sequential acquisitions of more than 15 major anesthesia groups in Texas.

The goal was explicit geographic market dominance. USAP grew to handle nearly half of all hospital-only anesthesia cases in Texas and earn approximately 60% of hospital anesthesia revenue paid by state insurers. The FTC sued both Welsh Carson and USAP in September 2023 for monopolization. A federal court dismissed Welsh Carson in May 2024 because it held only a 23% minority stake by that point. The FTC finalized a consent order in May 2025 requiring Welsh Carson to freeze USAP investments, reduce board representation to one non-chair seat, and seek pre-approval for future anesthesia investments under a 10-year term.

U.S. Anesthesia Partners (USAP)

USAP became the FTC's primary exhibit in healthcare PE antitrust enforcement. It illustrates how a roll-up can achieve pricing power that competition alone cannot undo. Headquartered in Houston, USAP controls approximately half of all hospital-only anesthesia cases in Texas and earns roughly 60% of all hospital anesthesia revenue paid by Texas commercial insurers.

A University of Chicago Booth School study published in July 2025 found anesthesia costs in Houston and Dallas markets jumped nearly 30% within two years of USAP acquiring the dominant local practices. Prices did not revert even after new competitors entered those markets. The Colorado Attorney General reached a separate agreement with USAP in February 2024 requiring divestiture of its Colorado anesthesia assets. Federal antitrust litigation against USAP continues into 2026.

North American Partners in Anesthesia (NAPA)

The nation's largest anesthesia staffing company by clinician count, NAPA employs 6,000 anesthesiologists and certified registered nurse anesthetists (CRNAs) at 500 facilities across 21 states. American Securities in New York and Leonard Green & Partners in Los Angeles jointly own the company. Four of NAPA's nine directors are executives from its PE general partners.

This governance structure illustrates the PMC model directly: fund managers control strategic decisions on staffing levels, contract negotiations, and facility expansion while clinicians manage patient care. NAPA has faced multiple hospital lawsuits alleging chronic understaffing. Cooperman Barnabas Medical Center in New Jersey recorded 286 adverse events in the first six months of 2022, attributed to NAPA understaffing. The hospital dismissed its anesthesiology chief for attending a meeting to address the issue, then ultimately formed its own anesthesiology department.

KKR

KKR's $9.9 billion acquisition of Envision Healthcare in 2018 was the largest single leveraged buyout of a physician staffing company. Envision delivered anesthesiology, emergency medicine, and other hospital-based specialty services across more than 1,800 clinical departments in 45 states. The investment thesis centered on hospital-based specialty consolidation broadly, not anesthesiology alone.

The investment ended in Chapter 11. Envision filed for bankruptcy in 2023, and KKR exited through the restructuring. The Envision collapse is now studied alongside the Steward Health Care bankruptcy as a case study in excessive debt load overwhelming a physician staffing platform on thin per-case margins.

Blackstone

Blackstone's exposure to anesthesia investing flows through TeamHealth, its physician staffing portfolio company providing anesthesiology and emergency medicine services across hundreds of US hospitals. Blackstone also served as a private credit lender to Envision Healthcare and acquired a partial stake in AMSURG through Envision's post-bankruptcy restructuring.

This dual role, as equity owner of a competing staffing platform and post-restructuring creditor to a rival, reflects Blackstone's strategy of holding multiple positions across the healthcare staffing ecosystem. Anesthesia practitioners evaluating employment offers from staffing platforms should know that TeamHealth competes directly with NAPA and remaining independent groups for the same hospital-based contracts.

TPG Growth and Cranemere Group

TPG Growth introduced the growth equity model to anesthesia staffing by purchasing a controlling stake in NorthStar Anesthesia in 2013. Rather than executing a geographic roll-up, TPG positioned NorthStar as a national anesthesia management and staffing company. The firm sold the majority stake to Cranemere Group in 2018, retaining a minority position.

Cranemere, a New York-based holding company, takes a structurally different approach from standard PE ownership. Instead of targeting a typical 4-7 year exit, it structures investments for indefinite ownership with management partners. NorthStar continues to operate under Cranemere today. The TPG-to-Cranemere secondary transaction illustrates one of the more common exit paths for mid-sized anesthesia platform investments.

Hellman & Friedman

Hellman & Friedman's backing of Sheridan Healthcare established the template that subsequent PE investors in anesthesiology applied at scale. Sheridan, founded in 1953, grew under H&F's ownership into the nation's largest anesthesia organization with national geographic reach. Hospital-based exclusive contracts formed its core competitive asset.

AmSurg acquired Sheridan in 2014 for $2.35 billion, validating the thesis that a scaled anesthesia management company could command a major acquisition multiple. Welsh Carson's creation of USAP applied the same playbook with greater geographic concentration and more aggressive pricing alignment across acquired practices. That strategy ultimately produced the FTC enforcement response that Sheridan never triggered.

Apollo Global Management

Apollo's anesthesia investing exposure is indirect but spans the country through Lifepoint Health and ScionHealth, which together control 235 combined hospital facilities, each with embedded anesthesia departments. Apollo acquired Lifepoint in 2018 and merged it with RegionalCare Hospital Partners. The firm then spun certain facilities into ScionHealth when Lifepoint subsequently acquired Kindred Healthcare in 2021.

Lifepoint now operates joint venture arrangements covering 78+ hospitals with 26 different health systems, including a 14-hospital partnership with Duke Health. For anesthesia investors and practitioners, Apollo's model represents the hospital system route to anesthesia market access. Controlling the facility ultimately means controlling the staffing contract.

Key Investment Trends in Anesthesia

Roll-Up Consolidation and Antitrust Enforcement

The serial acquisition strategy that defined anesthesia PE investing from 2012 to 2022 now faces structurally higher legal risk. The FTC's 2023 lawsuit against Welsh Carson and USAP, the Colorado AG's divestiture agreement with USAP in February 2024, and the Welsh Carson consent order finalized in May 2025 collectively mark a new enforcement posture toward healthcare roll-ups. Researchers estimate that FTC enforcement across 18 Texas markets alone would cut anesthesia expenditures by approximately $120 million per year. Pure geographic monopolization of a single hospital-based specialty is no longer a viable investment thesis.

State Legislative Wave

At least 19 states introduced legislation in 2025 to regulate private equity in healthcare, including California, New York, Colorado, and Texas. Indiana and Massachusetts passed oversight legislation in 2024. The US Senate Budget Committee's January 2025 bipartisan investigation focused on Prospect Medical Holdings and Lifepoint Health. It documented patterns of PE firms prioritizing short-term returns at the expense of patient care and called for greater federal oversight. This legislative accumulation is increasing deal timelines, due diligence costs, and disclosure requirements for PE investors pursuing healthcare acquisitions, including anesthesia practices.

Joint Ventures as a Growth Alternative

With direct roll-ups under scrutiny, PE-backed firms are increasingly structuring growth through joint ventures with nonprofit health systems. Lifepoint Health covers 78+ hospitals through JV arrangements with 26 health systems, providing access to new markets while potentially reducing antitrust exposure versus a standard merger. The JV model has accelerated most visibly in rehabilitation and behavioral health. Its logic applies directly to anesthesia: a hospital partner with nonprofit status provides access to facility staffing contracts without triggering the serial acquisition concerns that regulators now specifically target.

Quality and ESG Exposure

Patient outcome data continues to accumulate against PE-backed healthcare platforms. A 2023 JAMA study found hospital-acquired complications increased 25% at hospitals following PE acquisition, including a 27% rise in falls, a 38% increase in central line infections, and a doubling of surgical site infection rates. CMS star ratings for PE-owned hospitals average 2.5 stars versus a national average of approximately 3 stars. Some 25% of PE hospitals are rated 1 star compared to 9.7% nationally. The number of 1-star PE hospitals more than doubled from 10 to 23 between 2024 and 2025. For limited partners evaluating healthcare alternatives, these figures represent quantifiable ESG exposure in any portfolio holding with hospital-based physician staffing assets.

How to Evaluate Anesthesiology Private Equity Firms

Track record on patient outcomes should be the first filter for any evaluation, whether as a practitioner, LP, or hospital counterparty. CMS star ratings and the Medicare Hospital All Owners Information database allow investors and clinicians to assess a PE-owned facility's quality trajectory before committing. A facility with a declining CMS rating under PE ownership is a concrete red flag that cost-cutting has outpaced clinical investment.

Debt structure is the second critical dimension. LBO financing in healthcare loads debt onto portfolio companies rather than PE funds. This means interest payments compete directly with clinical staffing budgets.

Examine whether a firm has executed dividend recapitalizations (directing portfolio companies to take on new debt and pay proceeds to the PE owner) or sale-leaseback transactions (selling real estate to third parties and increasing ongoing lease obligations). Steward Health Care's 2024 bankruptcy, one of the largest hospital bankruptcies in decades, followed exactly this pattern under Cerberus Capital Management.

Exclusive contracting practices and noncompete clauses determine how much flexibility practitioners retain after joining a PE-backed group. PE-backed PMCs like USAP used exclusive facility contracts to bar competitors from hospital markets and aligned rates across acquired practices to maintain elevated pricing. Practitioners should review contract terms for noncompete geographic scope, exclusive arrangement clauses, and termination rights before signing with any PE-backed employer.

Regulatory compliance history rounds out the checklist. FTC enforcement actions, state AG investigations, and hospital lawsuits alleging understaffing are all searchable and should be reviewed before any engagement.

Which Firm Fits Your Needs?

Anesthesiologists and CRNAs evaluating employment with PE-backed groups should weigh clinical governance and staffing commitments above practice size. NAPA's national platform across 500 facilities offers geographic mobility. Its litigation history at Cooperman Barnabas Medical Center, Moses Taylor Hospital, and Renown Regional Medical Center makes per-facility staffing ratios an essential negotiation point.

NorthStar Anesthesia, under Cranemere's indefinite holding model, presents a lower exit-pressure risk profile. Without a fixed 4-7 year fund timeline, management has less structural incentive to compress staffing costs ahead of a sale. EBITDA growth pressure is less acute under Cranemere's long-hold framework than under a standard buyout structure.

Practice owners considering a PE acquisition offer should understand that roll-up buyers impose rate alignment, exclusive facility contracts, and noncompete clauses designed to concentrate market pricing power. In markets where USAP or similar platforms have already consolidated most hospital contracts, selling to the dominant player may generate an immediate premium but eliminate future competitive options entirely.

Owners should retain counsel with corporate practice of medicine experience and independently assess proposed debt loads. They should also negotiate for defined staffing minimums and board representation rights.

LPs building diversified alternatives portfolios should request full disclosure of dividend recapitalization history and sale-leaseback transactions for any healthcare holding before committing. The KKR-Envision and Cerberus-Steward collapses demonstrate that high-leverage physician staffing platforms face margin compression and regulatory headwinds. These risks can overwhelm returns within a standard PE hold period.

Firms with JV-structured hospital growth, like Apollo's Lifepoint model, may carry lower antitrust risk than pure roll-ups. Scrutiny of the underlying debt architecture remains essential regardless of deal structure.

Methodology

This guide to private equity anesthesia draws on peer-reviewed research published in JAMA Internal Medicine (2022), JAMA (2020 and 2023), and the Annals of Internal Medicine (2021), supplemented by regulatory enforcement records from the FTC and state attorneys general through May 2025. Hospital ownership data reflects the April 2025 release of a comprehensive PE hospital tracker covering CMS-enrolled facilities. Firm profiles are based on documented deal histories, regulatory filings, and public company disclosures available as of early 2026. Firms are included only where participation in anesthesiology private equity or hospital-based physician staffing can be verified through documented transactions. No AUM figures are cited without documentary support, and the AUM column is omitted from the comparison table because verifiable figures are available for fewer than half the firms covered.